Journal Homepage: - www.journalijar.com

INTERNATIONAL JOURNAL OF ADVANCED RESEARCH (IJAR)

Article DOI: 10.21474/IJAR01/19800
DOI URL: http://dx.doi.org/10.21474/IJAR01/19800

RESEARCH ARTICLE

PROTECTION FROM CARDIOVASCULAR DISEASES USING BETA-BLOCKERS: A LITERATURE REVIEW

Kanika Kuntal

Manuscript Info

Manuscript History
Received: 31 August 2024
Final Accepted: 30 September 2024
Published: October 2024

Key words:-
Beta-blockers, Cardiovascular Protection, Beta-Adrenergic Receptors, Heart Rate, Blood Pressure, Myocardial Oxygen Demand, Cardiac Output, Effects of Epinephrine and Norepinephrine

Abstract

The role of beta-blockers in cardiovascular protection has been a hot topic of research. Myocardial oxygen demand, heart rate, and blood pressure are all reduced as the action of epinephrine and norepinephrine on beta-adrenergic receptors is inhibited. In congenital heart disease people want from admission towards evaluating the hypertensive status with beta-blocker monitoring activity. Also, it looks at the adverse effects of beta blockers including bradycardia, tiredness and asthma attacks. The advantages and disadvantages of selective and non-selective beta-blockers are summarized based on clinical use and efficacy. Such relative benefits emphasize the need for individualization since the above strategies are aimed at augmenting the therapeutic actions of beta blockades impose a serious risk of side effects. Taken together, beta-blockers have been integral in the treatment of different cardiovascular pathologies leading to better health of patients.

Introduction:-

By affecting the workload and oxygen need of heart, beta-blockers offer a protective shield against cardiovascular risk[1,2].

a. Lowers Heart Rate: A reduction in heart rate by beta-blockers leads to a lower demand for oxygen by the heart.
b. Lowering Blood Pressure: They assist in lowering blood pressure by decreasing the amount of blood that the heart pumps.
c. Anti-arrhythmic Actions: They are useful in avoiding abnormal heart rhythms or arrhythmia by blocking excess conduction or slow conduction of electrical power in the heart.
d. Reducing Cardiac Contractility: They lower the power of contraction of the heart muscles, an effect which is desirable in treating heart failure.
e. Alleviating Stress: Beta-blockers lower blood pressure by countering the physical stress that results from the action of adrenaline.

These properties further enhance the use of beta blockers in the management of hypertension, angina, heart failure, and arrhythmias[3,4].

Further, this review provides an overview of the current and emerging changes in the field of beta-blocker therapy. The relative effectiveness of various taking beta-blockers and their discriminative effects on different strata of patients gives further causes of the need for more in-depth research. Often plead for selective beta-blockers because they do not have as much respiratory incidental effects as their non-selective counterparts. However, these two

Corresponding Author:- Kanika Kuntal

classes still have important roles to play in everyday clinical practice given the availability of substantial evidence on their benefits to the reduction of morbidity and mortality. By synthesising the available literature and identification of literature silos, this review seeks to provide evidence for better clinical management of patients with cardiovascular diseases.

Battling heart problems is nowhere near straightforward as this review explains. It considers the particulars of using beta-blockers, outlining their cardioprotective effects and adverse reactions. There are certain types of beta blockers that are used selectively owing to the relatively lesser side effects they produce, especially with patients suffering from respiratory disorders, versus their counterparts who are non-selective beta blockers who have effects on a wider range of adrenergic receptors. This is worth pointing out in order to customize patients' treatment, enhance therapeutic outcomes, and limit side effects. Clinical analysis shows the significance of beta blockers' usage within the sphere of heart diseases prevention supported by the evidence and guidelines from the leading cardiovascular societies. This consolidated understanding thus helps the clinician to avoid errors thus leading to a low complication rate in overstated management of patients susceptible to cardiovascular risks[1,3,4].

Mechanism of Action

The beta-blockers mainly affect the epinephrine and norepinephrine hormones received by the beta-adrenergic receptors in order to decreases heart rate and blood pressure.

This mechanism involves:

- Decreasing myocardial oxygen demand.
- Reducing cardiac output.
- Inhibiting renin release from the kidneys.
- Regulating sympathetic tone by stressful life activities.

Beta-blockers affect the cardiovascular system in various physiological manners because the interaction is not a simple one. Beta-blockers, at cellular level of action, act by blocking or by antagonizing the effects of endogenous catecholamines through occupying the specific sites on beta-adrenergic receptors. Consequently, there is a series of following effects, which cause a reduction in both the rate and strength of the heartbeat and the blood pressure[5].

Beta-blockers also act on other organs and systems of the general body that is involved with cardiovascular functions not limited to the heart[6,7]. For example, whilst reducing renin release from the kidneys, beta-blockers indirectly act on the renin-angiotensin-aldosterone system (RAAS) responsible for blood pressure control and fluid balance. In addition, their inhibition of sympathetic nerves has positive effects on the cardiovascular system because chronic activation of sympathetic nerves is overtly toxic on the heart and blood vessels[8,9].

Indications

Beta-blockers are commonly used to treat a variety of cardiovascular conditions, including:

- Hypertension
- Heart failure
- Angina pectoris
- Hebrew Heart Jet activity (for example, atrial fibrillation, ventricular tachycardia)
- The Percent Expressed figure shows lower rates of utilization in secondary prevention of patients after myocardial infarction
- Selected types of the aortic dissection[6]

The use of beta-blockers in various cardiovascular disorders is therefore because these drugs interact with the current pathophysiological processes. In hypertension, the properties of reducing blood pressure are most valuable in their case. In heart failure, beta blockers are useful for lowering the application on the heart and gradually remodeling of the left ventricle. In the chronic stable angina, these drugs cause reduction in myocardial oxygen consumption and are effective in reducing the frequency and intensity of episodes of angina pectoris [9,10].

Beta-blockers have variety of uses in the setting of arrhythmias. They can reduce the heart rate in conditions such as atrial fibrillation, helping with symptoms and perhaps even decreasing the risk of future problems. Beta blockers in

their role in managing ventricular arrhythmias prevent such individuals from experiencing a life-threatening event through regulation of electrical instability in the heart[11].

Beta-blockers in the secondary prevention following myocardial infarction are justified by the reduction of the risk of reinfarction and sudden cardiac death[7]. These medications decrease cardiac workload through pre-and post-ganglionic sympathetic blockade, thus reducing myocardial oxygen demand and protecting the vulnerable myocardium during the postinfarction healing phase[12].

Beta-blockers are again active in the medical management of certain variants of aortic dissection, particularly the one that affects the descending aorta. They also lower the shear stress to the aortic wall by decreasing the rate and pressure of heartbeat thus possibly slowing down the expansion of the dissection and also the chances of a filler.

Cardiovascular Protection

Beta-blockers have demonstrated several protective effects on the cardiovascular system:

- Reduced mortality in heart failure patients: Several small and large phase III trials have demonstrated better mortality outcomes in patients with low ejection fraction heart failure.
- Decreased risk of sudden cardiac death: They include blockers that can prevent life-threatening forms of irregular heartbeat known as arrhythmia.
- Improved outcomes after myocardial infarction: Beta-blockers when used as post-MI medications have shown better outcomes and therefore initiating the therapy in the early months after MI has been linked to lower mortality rates[5].
- Blood pressure control in hypertensive patients: Beta blockers successfully reduce blood pressure, decreasing the potential of cardiovascular events as well as of end-organ damage.
- Slowed progression of aortic aneurysms: Certain population groups are said to benefit from beta-blockers in a way that may slow down the expansion of aneurysms in the aortas[12].

There is voluminous evidence that beta-blockers exert a whole lot of cardioprotective properties that has implications that transcend its immediate hemodynamic impact data. Despite high morbidity and mortality rates associated with heart failure with reduced ejection fraction, continued beta-blocker use has been demonstrated to cause reverse remodeling of the left ventricle with enhanced function and morphology over the long term. Much of the mortality benefit seen in the clinical trials is believed to be due to this effect[13].

The use of beta-blockers in reducing sudden cardiac death is important in high-risk patients, those with history of myocardial infarction or heart failure. These drugs help prevent the death by controlling ventricular arrhythmias and minimizing the effect of acute ischemic events[6,13].

In particular, the efficacy of beta-blockers for protecting against sudden cardiac death is most significant for patients at high risk of developing the condition: those who have previously suffered a heart attack or who have been diagnosed with heart failure. As with controlling of ventricular arrhythmias and decreasing the effects of acute ischemic events, these drugs help to increase the following of life[2,3,6,10,13].

In hypertension treatment, therefore, the cardiovascular protection that goes along with beta blockers is not just about lowering blood pressure. Such agents have been established to have positive effects on the endothelium, arterial wall elastic properties, and the rate of change of atherosclerosis, all of which define long-term cardiovascular status.

In the course of using beta-blockers as a preventive measure, there is controversy regarding the drug's ability to reduce the rate of growth of aortic aneurysms. Some papers have positive outcomes which are more significant for patients with Marfan syndrome but for other patients the results are not confirmed yet rigorously. More studies should be conducted in order to define possible ways of how beta-Blockers may affect the aneurysm enlargement and to determinate which patients may profit from this treatment[2,3,10,13].

Types of Beta Blockers

Beta-blockers can be classified into several categories based on their selectivity and additional properties:

- Cardioselective beta-blockers (e.g., metoprolol, atenolol, bisoprolol): These agents mainly act on β1 receptors of the heart, and therefore, the effect on other organs may be less dangerous.
- Non-selective beta-blockers (e.g., propranolol, carvedilol, timolol): These drugs work on both β1 and β2 adrenergic receptors and while it makes the drugs to have a wider duration of action it also poses higher threats to specific side effects.
- Beta-blockers with additional vasodilatory properties (e.g., nebivolol, carvedilol): Such agents offer other advantages by of course, through some process like the generation of nitric oxide or acting as alpha- adrenergic antagonist[6].

The invention of different classes of beta-blockers has not only given rise to more selective therapeutic strategies. Beta-blockers that selectively block the β1 receptors in the cardiac muscles are less likely to cause effects on the β2 receptors on other tissues as are those found in the lungs and blood vessels. This selectivity can be of special use in treatment of patients with such illnesses as asthma or chronic obstructive pulmonary disease, because non-selective beta-blockers can cause bronchospasm[7].

It appears that, despite non-selective beta-blockers bring linked to certain side effects risks, they may have benefits in selected situations. For instance, they can help in elimination of degrees of portal hypertension in the patients with liver cirrhosis or in certain types of tremors[15].

Therefore, development of beta blockers with added vasodilatory action could be considered a step forward. Like other agents, nebivolol and carvedilol demonstrate beta-blocking activity in conjunction with nitric oxide-induced vasodilation or non-selective alpha-adrenergic antagonism. They provide further features of antihypertensive therapy and could potentially have metabolic benefits compared with conventional BBs.

The selection of particular types of beta-blockers ultimately depends on the specific cardiovascular disease to be treated the presence of other related diseases, as well as the response of specific individuals to drugs. One of the reasons that beta-blocker therapy has taken hold and is useful in cardiovascular medicine is the flexibility in dosing and the options for the individual patient[16].

Comparative Effectiveness

Studies have shown varying degrees of cardiovascular protection among different beta-blockers:

- Some meta-analysis have evaluated predictors of mortality and cardiovascular event reduction by different beta-blockers.
- There is some belief that there are new types of beta-blockers containing vasodilators that can have additional advantages in patients with heart failure or hypertension.
- Depending on the patient's cardiovascular pathology, characteristics, and contraindications to certain substances, one or another beta-blocker may be used[6,15].

The seriousness of the comparative evaluation of various beta-blockers has been an area of intense research priorities. It is well understood that all beta-blockers act by blocking beta-adrenergic receptors; however, the affinities and limb effects of its pharmacological classes are not the same.

In heart failure, carvedilol, metoprolol succinate, and bisoprolol have shown overall survival advantage in multicenter trials. Several investigations have pointed out that carvedilol might produce better results than metoprolol tartrate, probably owing to its added alpha-adrenergic blocking and antioxidant effects. Yet, the clinical relevance of these differences still remains an object of debate.

When it comes to hypertension treatment, the situation gets a bit blurred. Atenolol, the typical beta-blocker, has been reported to be less efficacious in decreasing CVD risk than other classes of antihypertensive in some trials. But modern Beta-blockers such as nebivolol have shown reduction in central blood pressure and improved arterial stiffness, probably which will provide better CV long-term outcomes[16].

Secondary prevention after myocardial infarction Multiple β-blockers are beneficial the benefit does not seem the be higher with one β-blocker over another. In such situation, depending on frequency of dosing, cost and characteristics of individual patients and certain pathologies the choice has to be made[17].

Nevertheless, there is evidence of variability in the benefits of beta-blockers related to the particular outcome assessed: mortality or hospitalization rate, as well as patients' cohort. In such cases, the decisions regarding the treatment may be made depending on the available evidence and patient's characteristics[18,19,20].

Side Effects and Contraindications

While generally well-tolerated, beta-blockers can cause various side effects and may be contraindicated in certain patient populations:

- The side effects may include fatigue, bradycardia and broncospasmation amongst others.
- Long term use of the medication may lead to sleep disturbances, sexual dysfunction and cold limbs.
- Caution is recommended in patients with asthma, COPD, diabetes and PVD.
- Patients that have their β-blockers withdrawn abruptly stand high risks of rebound hypertension or worsening of the angina symptoms.

These side effects are generally due to the drugs' basic mechanism of action and may differ at least to some extent depending on the specific beta-blocker employed and its selectivity. Some of the side effects include fatigue where the drug is believed to have an impact on cardiac output and possibly central nervous system. Of course, bradycardia per se is desirable if not an intended goal of the initiated beta-blocker therapy; however, excessively low heart rate in combination with one's reduced reserves due to old age or presence of conduction abnormalities is dangerous.

The increased airway resistance is the reason why non-selective beta-blockers present the bigger issue, as they block also the β2 receptors. This risk is usually relatively higher for cardioselectiveagents, However the application of great caution is advised in cases of patients with other illnesses that cause a strained airway.

The metabolic effects of beta-blockers, with special reference to their influence on carbohydrate metabolism and lipid patterns, have remained under debate. In contrast to older nonspecific beta-blockers, newer agents, particularly those with recognisedvasodilating activity, are considered to possess more favourable metabolic actions[23].

Another drawback when taking beta-blockers is that they may precipitate or worsen peripheral vascular disease, which may be present in some would-be weightlifters. It is hypothesised that this effect is as a result of unopposed alpha- adrenergic activity in the peripheral circulation.

Specifically, clients on beta-blockers ought to reduce this medication dosing progressively, in light of the reality that drastic stoppage results in what is known as beta-blocker withdrawal syndrome. Withdrawal symptoms are rapid increase of sympathetic tone with possible development of rebound hypertension, tachycardia or worsening of the angina. This risk emphasises the importance of titre intervention when altering the beta-blocker regimen or stopping the therapy[20,21,23].

Guidelines

Major cardiovascular societies have issued guidelines recommending beta-blockers as first-line or second-line therapy for various cardiovascular conditions:

- The basic guidelines of American College of Cardiology (ACC)/ American Heart Association (AHA) for the management of heart failure include oral and IV beta-blockers as a class I indication for heart failure with reduced LVEF, in post-MI care, and some specific arrhythmias.
- The European Society of Cardiology (ESC) guidelines also recommend the use of beta-blockers for different CV conditions.
- Beta-blockers are listed in all current national and international hypertension guidelines as a second-line antihypertensive drug when there are alleged signs of coronary heart disease.

The recent inclusion of beta-blockers in major cardiovascular guidelines points on the fact that this class of drugs is effective when applied in different clinical cases. Beta-blockers are also as a best practice medicine forheart failure with preserved ejection fraction(HFrEF) and are stated to be advised in all patients that can tolerate them but in whom they are contraindicated[10,11].

Recommendations for individuals with a history of myocardial infarction are as follows: early commencement of beta-blocker therapy if the patient is hemodynamically stable; long-term maintenance of beta-blockers, at least for 3 years and ideally lifelong in patients with reduced left ventricular ejection fraction or other high-risk markers.

Beta-blockers are invaluable in the administration of management of arrhythmias in both the acute and the chronic phase. They are used as anticoagulants in rhythm control of atrial fibrillation and as anti-arrhythmic measures in array of contexts[3,4].

Beta- blockers' place within the antihypertensive management has changed over the years. As first-line antihypertensive therapy they are not used for all patients with hypertension anymore, but are there as an option, especially in patients with certain comorbidities or risk factors that will benefit from beta-blockade.

Several guidelines should also be noted that they are working documents and are updated with the change of evidence and advancement in the practice. Therefore, the current versions of these guidelines should be used by healthcare providers when making management decisions[5,7,19].

Ongoing research

Several areas of ongoing research aim to optimize the use of beta-blockers in cardiovascular protection:

- Investigation into optimal dosing strategies: Researches are now trying to find out if a lower strength of beta blockers can be as effective in helping to reduce the heart rate helping to lessen the symptoms of nervousness, tremors, difficulty in sleeping etc. while having fewer side effects.
- Exploration of potential benefits in specific patient subgroups: Studies are focusing on intolerance of beta-blockers among some groups like patients diagnosed with heart failure with preserved ejection fraction or those who possess specific genetic polymorphisms.
- Development of novel beta-blockers with improved safety profiles: New agents are being developed to reduce side effects but at the same time to reduce or even improve cardiovascular protection.
- Combination therapies: They are doing research to identify how better the betablockers together with other cardiovascular medicines are blockers.
- Long-term outcomes: Several long-term large-scaled prospective trials are evaluating the consequences of beta-blocker treatment in ischemic heart disease on cardiovascular outcomes and mortality.

Beta-blockers represent an area of active research, with several promising directions of investigation. A relatively new concept is referred to as "dose tailing" with the intent of learning whether similar outcomes can be derived from use of lesser amounts of beta-blockers but with few side effects. They believed that this could best be applied where a patient is old or has other diseases that are likely to cause them to be sensitive to the side effects.

Despite the fact that beta-blockers had negligible effect in early trials, their role in heart failure with preserved ejection fraction (HFpEF) remains speculative. Despite a clear positive effect of these drugs in heart failure with reduced ejection fraction, it remains uncertain whether they are effective in HFpEF. Current studies are being done to determine if certain kind of drug or patients with certain characteristics in the HFpEF group have benefits from this therapy.

Pharmacogenomics is another area of research in beta blockers study. Research is being conducted about the possible effect of polymorphic inserted of BRA and other related genes on the response to the therapy of beta-blockers. It is possible in the future that this line of research might help to develop individualised treatment strategies.

New, more selective or with other suitable therapeutic profiles of Beta-blockers is still under development. These efforts seek to develop new agents that provide or have a better level of CV protection that traditional b-blockers while avoiding the unpleasant side effects.

Some areas of study within combination therapies involve finding out how effective certain beta blocker drug is when used in combination with other cardiovascular drugs. This include assessments of fixed dose combinations which are likely to enhance the compliance to drugs and possibly have additional therapeutic advantages.

Several years and/or post-treatment are essential for identifying long-term advantages of the beta-blocker therapy on the cardiovascular performance and mortality rates. These studies are especially valuable because many cardiovascular disorders are chronic, and these drugs may be used for many years.

Conclusion:-

Beta-blockers have been widely used in cardiovascular disease for several decades, and current research focuses on the fine-tuning of their application and the definition of their possible new roles in the prevention of cardiovascular disease. The outcomes of these endeavours are expected to influence subsequent guidelines and the clinical practice regarding beta blockers in cardiovascular medicine, most probably introducing more appropriately tailored applications in the setting of AMI.

A literature review on this topic can only be done effectively if a research conducted a search of current recent literature, peer-reviewed articles, meta-analyses and systematic reviews. Furthermore, the reader may refer to the current guidelines from the major cardiac societies and also keep abreast of recent trials of beta-blockers for cardiovascular risk reduction.

References:-

[1] De Sutter J, Mendes M, Franco OH. Chapter 19 Cardioprotective drugs. In: Gielen S, De Backer G, Piepoli MF, Wood D, editors. The ESC Textbook of Preventive Cardiology. 2nd ed. United Kingdom: Oxford University Press, 2016.
[2] Steg G, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–2619.
[3] Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013; 34: 2949–3003.
[4] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 2129-2200.
[5] Bangalore S., Messerli F. H., Kostis J. B., Carl J. Pepine 2007 Cardiovascular Protection Using Beta-Blockers: A Critical Review of the Evidence, Journal of the American College of Cardiology, 50, 563-572 DOI:10.1016/j.jacc.2007.04.060
[6] Ziff, O.J., Samra, M., Howard, J.P. et al. Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Med 18, 103 (2020). https://doi.org/10.1186/s12916-020-01564-3
[7] Chan You S, Krumholz HM, Suchard MA, Schuemie MJ, Hripcsak G, Chen R, Shea S, Duke J, Pratt N, Reich CG, Madigan D, Ryan PB, Woong Park R, Park S. Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients: A Large-Scale Multicenter Observational Study. Hypertension. 2021 May 5;77(5):1528-1538. doi: 10.1161/HYPERTENSIONAHA.120.16402. Epub 2021 Mar 29. PMID: 33775125; PMCID: PMC8035236
[8] Fici F, Robles NR, Tengiz I, Grassi G. Beta-Blockers and Hypertension: Some Questions and Answers. High Blood Press Cardiovasc Prev. 2023 May;30(3):191-198. doi: 10.1007/s40292-023-00576-3. Epub 2023 May 11. PMID: 37166681
[9] Martínez-Milla J, Raposeiras-Roubín S, Pascual-Figal DA, Ibáñez B. Role of Beta-blockers in Cardiovascular Disease in 2019. Rev EspCardiol (Engl Ed). 2019 Oct;72(10):844-852. English, Spanish. doi: 10.1016/j.rec.2019.04.014. Epub 2019 Aug 8. PMID: 31402328.
[10] Dr. Ines Frederix, Dr. Michael Mcintosh, 2017, Cardio protective drugs: Beta-blockers, European Society of Cardiology, URL:https://www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/Treatment-goals/Cardio-Protective-drugs/beta-blockers?form=MG0AV3
[11] World Anti-Doping Agency (WADA) 2018, Cardiovascular Conditions: The Therapeutic Use of Beta-Blockers in Athletes, URL:https://www.wada-ama.org/sites/default/files/2022-01/cardiovascular_conditions_v_2.0_jan2018_en.pdf?form=MG0AV3
[12] Cleveland Clinic Year, 2022, Beta-blockers: Types, Uses and Side Effects, URL:https://my.clevelandclinic.org/health/treatments/22318-beta-blockers?form=MG0AV3
[13] Chatterjee S, Biondi-Zoccai G, Abbate A, D'Ascenzo F, Castagno D, Van Tassell B et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis BMJ 2013; 346 :f55 doi:10.1136/bmj.f55

[14] Chen S, Tian P, Estau D and Li Z (2023) Effects of β-blockers on all-cause mortality in patients with diabetes and coronary heart disease: A systematic review and meta-analysis. Front. Cell Dev. Biol. 11:1076107. doi: 10.3389/fcell.2023.1076107
[15] Massalee R and Cao X (2024) Repurposing beta-blockers for combinatory cancer treatment: effects on conventional and immune therapies. Front. Pharmacol. 14:1325050. doi: 10.3389/fphar.2023.1325050
[16] Eraky AM, Yerramalla Y, Khan A, Mokhtar Y, Alamrosy M, Farag A, Wright A, Grounds M, Gregorich NM. Beta-Blockers as an Immunologic and Autonomic Manipulator in Critically Ill Patients: A Review of the Recent Literature. Int J Mol Sci. 2024 Jul 24;25(15):8058. doi: 10.3390/ijms25158058. PMID: 39125627; PMCID: PMC11311757
[17] Kramer JM, Curtis LH, Dupree CS, Pelter D, Hernandez A, Massing M, Anstrom KJ. Comparative effectiveness of beta-blockers in elderly patients with heart failure. Arch Intern Med. 2008 Dec 8;168(22):2422-8; discussion 2428-32. doi: 10.1001/archinternmed.2008.511. PMID: 19064824.
[18] Parker ED, Margolis KL, Trower NK, Magid DJ, Tavel HM, Shetterly SM, Ho PM, Swain BE, O'Connor PJ. Comparative effectiveness of 2 β-blockers in hypertensive patients. Arch Intern Med. 2012 Oct 8;172(18):1406-12. doi: 10.1001/archinternmed.2012.4276. PMID: 22928181; PMCID: PMC4120749.
[19] Go AS, Yang J, Gurwitz JH, Hsu J, Lane K, Platt R. Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure. Am J Cardiol. 2007 Aug 15;100(4):690-6. doi: 10.1016/j.amjcard.2007.03.084. Epub 2007 Jun 26. PMID: 17697830.
[20] Hans-Peter Marti, Abel Alberto PavíaLópez& Pedro Schwartzmann (2024) Safety and tolerability of β-blockers: importance of cardioselectivity, Current Medical Research and Opinion, 40:sup1, 55-62, DOI: 10.1080/03007995.2024.2317433
[21] Vögele, A., Johansson, T., Renom-Guiteras, A. et al. Effectiveness and safety of beta blockers in the management of hypertension in older adults: a systematic review to help reduce inappropriate prescribing. BMC Geriatr 17 (Suppl 1), 224 (2017). https://doi.org/10.1186/s12877-017-0575-4
[22] Ko DT, Hebert PR, Coffey CS, et al. Adverse Effects of β-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials. Arch Intern Med. 2004;164(13):1389–1394. doi:10.1001/archinte.164.13.1389
[23] Bularga A. Beta blockers in cardiovascular medicine: Efficacy and safety profile. 2024;8(3):259.